New 16" Chicos Collar Statement Wom Choker Fashion Necklace Gift Today's only New 16" Chicos Collar Statement Wom Choker Fashion Necklace Gift Today's only $9 New 16" Chicos Collar Statement Necklace Choker Gift Fashion Wom Jewelry & Watches Fashion Jewelry Necklaces & Pendants Collar,Jewelry & Watches , Fashion Jewelry , Necklaces & Pendants,Choker,Statement,Fashion,16",$9,/donship642041.html,Gift,Necklace,Chicos,fortunebyfame.com,New,Wom Collar,Jewelry & Watches , Fashion Jewelry , Necklaces & Pendants,Choker,Statement,Fashion,16",$9,/donship642041.html,Gift,Necklace,Chicos,fortunebyfame.com,New,Wom $9 New 16" Chicos Collar Statement Necklace Choker Gift Fashion Wom Jewelry & Watches Fashion Jewelry Necklaces & Pendants
New 16" Chicos Collar Statement Necklace Choker Gift Fashion Wom
$9
New 16" Chicos Collar Statement Necklace Choker Gift Fashion Wom
|||
Item specifics
Condition:
New without tags: A brand-new, unused, and unworn item (including handmade items) that is not in ... New without tags: A brand-new, unused, and unworn item (including handmade items) that is not in original packaging or may be missing original packaging materials (such as the original box or bag). The original tags may not be attached.
Shape:
No Pendant
Country of Origin:
China
Country/Region of Manufacture:
China
Style:
Statement
Modified Item:
No
Certification:
None
Base Metal:
Alloy
Length (inches):
16
Main Color:
Silver+Gray+Silver+Clear
Country of Manufacture:
China
Gongying:
nvwangzhuanshu20000-003-jin10
Material:
Shell
Theme:
Holiday
Pendant/Locket Type:
No Locket
Jewelry Type:
Necklace
Modern/ Vintage:
Vintage
Gender:
Female
Fine_Fashion:
Fashion
Type:
Necklace
Secondary Stone:
Not Applicable
Main Stone Color:
Gray
Color:
Silver+Gray+Silver+Clear
Item Length:
16 in
Main Stone Treatment:
Filling
Main Stone:
Glass
Main Stone Creation:
Simulated
Brand:
Chico's
Metal:
Alloy
Main Stone Shape:
Oval
UPC:
Does not apply
New 16" Chicos Collar Statement Necklace Choker Gift Fashion Wom
Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.
Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.
The Author Information section provides general guidelines and requirements for specific article types.
Are you looking for the latest rheumatology research findings presented in an easily accessible format to share with patients, carers or colleagues?
ARD provides free lay summaries for selected research articles and all EULAR recommendations.
These aim to clearly explain the results of the research studies as well as any implications for treatment of the specific condition. The summaries are written in plain language in a consistently structured format and checked for accuracy and readability by experts and patient representatives.
The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE
To cite: Vital EM, Merrill JT, Morand EF, et al. Ann Rheum Dis. doi: 10.1136/annrheumdis-2021-221425
Read the full article here: link
Objective: To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups.
Conclusions: Overall, this study supports the consistent efficacy and safety of anifrolumab across a range of patients with moderate-to-severe SLE. In a few subgroups, small sample sizes limited conclusions from being drawn regarding the treatment benefit with
anifrolumab.
